Risk factors

BlackSky faces significant operating risks centered on satellite manufacturing failures, unproven market scale, and heavy dependence on government contracts.

Barinthus Biotherapeutics relies heavily on early-stage clinical candidates utilizing novel proprietary platforms like ChAdOx, MVA, and SNAP-TI. The company faces significant financial hurdles, requiring ongoing capital raises while lacking approved products or material revenue. Future success depends heavily on successful clinical trials, regulatory approvals, and establishing commercial and intellectual property infrastructure globally.

Cibus faces going concern doubts with $14.4 million in cash versus $19.9 million in current liabilities.

Cardio Diagnostics is a pre-revenue medical diagnostics company relying heavily on external financing and key university-licensed intellectual property. The company faces severe operational, competitive, and regulatory risks in the unproven epigenetic and cardiovascular testing markets.

Cognition Therapeutics is an early-stage biopharmaceutical company dependent on the success of its lead product candidate, zervimesine, for Alzheimer's and other diseases. The company faces significant financial risks, including net losses, going concern doubts, and potential Nasdaq delisting due to low stock price. Operations rely heavily on external capital raising, non-dilutive NIA grants, and successful clinical trial execution.

Context Therapeutics is an early-stage biopharmaceutical company dependent on raising capital to fund development of its key therapeutic candidates CTIM-76, CT-95, and CT-202. The company relies on a small team of twelve employees and external third-party manufacturers and collaborators.

Dakota Gold relies entirely on external equity financing and gold prices to fund its pre-revenue Black Hills exploration projects.

DUKE Robotics operates with minimal staff and capital, facing heavy reliance on Israeli operations and military conflict risks, plus government contracts for drone technology.

DXLG faces concentration risks tied to its DXL big-and-tall apparel brand, its single distribution center in Canton, Massachusetts, and reliance on third-party manufacturers.

Dynamix Corp is a special purpose acquisition company facing execution, redemption, and regulatory risks typical of blank check companies.

Clinical-stage biopharmaceutical company focused on developing its lead drug candidate, tegoprubart.

Erasca focuses exclusively on the unproven RAS/MAPK pathway, relying heavily on the naporafenib clinical program and third-party manufacturers.